311 related articles for article (PubMed ID: 34921220)
1. No neutralizing effect of pre-existing tick-borne encephalitis virus antibodies against severe acute respiratory syndrome coronavirus-2: a prospective healthcare worker study.
Kohler P; Jonsdottir HR; Risch L; Vernazza P; Ackermann-Gäumann R; Kahlert CR
Sci Rep; 2021 Dec; 11(1):24198. PubMed ID: 34921220
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on the European subtype: systematic review and meta-analysis.
Domnich A; Panatto D; Arbuzova EK; Signori A; Avio U; Gasparini R; Amicizia D
Hum Vaccin Immunother; 2014; 10(10):2819-33. PubMed ID: 25483679
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2-Specific Neutralizing Antibody Responses in Norwegian Health Care Workers After the First Wave of COVID-19 Pandemic: A Prospective Cohort Study.
Trieu MC; Bansal A; Madsen A; Zhou F; Sævik M; Vahokoski J; Brokstad KA; Krammer F; Tøndel C; Mohn KGI; Blomberg B; Langeland N; Cox RJ;
J Infect Dis; 2021 Feb; 223(4):589-599. PubMed ID: 33247924
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the European tick-borne encephalitis vaccine against Omsk hemorrhagic fever virus.
Chidumayo NN; Yoshii K; Kariwa H
Microbiol Immunol; 2014 Feb; 58(2):112-8. PubMed ID: 24329534
[TBL] [Abstract][Full Text] [Related]
5. Broad and potent neutralizing human antibodies to tick-borne flaviviruses protect mice from disease.
Agudelo M; Palus M; Keeffe JR; Bianchini F; Svoboda P; Salát J; Peace A; Gazumyan A; Cipolla M; Kapoor T; Guidetti F; Yao KH; Elsterová J; Teislerová D; Chrdle A; Hönig V; Oliveira T; West AP; Lee YE; Rice CM; MacDonald MR; Bjorkman PJ; Růžek D; Robbiani DF; Nussenzweig MC
J Exp Med; 2021 May; 218(5):. PubMed ID: 33831141
[TBL] [Abstract][Full Text] [Related]
6. A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans.
Orlinger KK; Hofmeister Y; Fritz R; Holzer GW; Falkner FG; Unger B; Loew-Baselli A; Poellabauer EM; Ehrlich HJ; Barrett PN; Kreil TR
J Infect Dis; 2011 Jun; 203(11):1556-64. PubMed ID: 21592984
[TBL] [Abstract][Full Text] [Related]
7. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
8. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
9. Confirmed exposure to tick-borne encephalitis virus and probable human cases of tick-borne encephalitis in Central/Northern Anatolia, Turkey.
Ergünay K; Saygan MB; Aydoğan S; Litzba N; Sener B; Lederer S; Niedrig M; Hasçelik G; Us D
Zoonoses Public Health; 2011 May; 58(3):220-7. PubMed ID: 20604912
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of SARS-CoV-2 Specific and Neutralizing Antibodies over Seven Months after Symptom Onset in COVID-19 Patients.
Zhu L; Xu X; Zhu B; Guo X; Xu K; Song C; Fu J; Yu H; Kong X; Peng J; Huang H; Zou X; Ding Y; Bao C; Zhu F; Hu Z; Wu M; Shen H
Microbiol Spectr; 2021 Oct; 9(2):e0059021. PubMed ID: 34550000
[TBL] [Abstract][Full Text] [Related]
11. Stable and Highly Immunogenic MicroRNA-Targeted Single-Dose Live Attenuated Vaccine Candidate against Tick-Borne Encephalitis Constructed Using Genetic Backbone of Langat Virus.
Tsetsarkin KA; Maximova OA; Liu G; Kenney H; Teterina NL; Pletnev AG
mBio; 2019 Apr; 10(2):. PubMed ID: 31015334
[TBL] [Abstract][Full Text] [Related]
12. Ability of inactivated vaccines based on far-eastern tick-borne encephalitis virus strains to induce humoral immune response in originally seropositive and seronegative recipients.
Maikova GB; Chernokhaeva LL; Rogova YV; Kozlovskaya LI; Kholodilov IS; Romanenko VV; Esyunina MS; Ankudinova AA; Kilyachina AS; Vorovitch MF; Karganova GG
J Med Virol; 2019 Feb; 91(2):190-200. PubMed ID: 30204244
[TBL] [Abstract][Full Text] [Related]
13. Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017.
Albinsson B; Vene S; Rombo L; Blomberg J; Lundkvist Å; Rönnberg B
Euro Surveill; 2018 Jan; 23(3):. PubMed ID: 29386094
[TBL] [Abstract][Full Text] [Related]
14. Molecular Basis of a Protective/Neutralizing Monoclonal Antibody Targeting Envelope Proteins of both Tick-Borne Encephalitis Virus and Louping Ill Virus.
Yang X; Qi J; Peng R; Dai L; Gould EA; Gao GF; Tien P
J Virol; 2019 Apr; 93(8):. PubMed ID: 30760569
[TBL] [Abstract][Full Text] [Related]
15. Post-exposure administration of chimeric antibody protects mice against European, Siberian, and Far-Eastern subtypes of tick-borne encephalitis virus.
Matveev AL; Kozlova IV; Stronin OV; Khlusevich YA; Doroshchenko EK; Baykov IK; Lisak OV; Emelyanova LA; Suntsova OV; Matveeva VA; Savinova JS; Tikunova NV
PLoS One; 2019; 14(4):e0215075. PubMed ID: 30958863
[TBL] [Abstract][Full Text] [Related]
16. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers.
Marot S; Malet I; Leducq V; Zafilaza K; Sterlin D; Planas D; Gothland A; Jary A; Dorgham K; Bruel T; ; Burrel S; Boutolleau D; Schwartz O; Gorochov G; Calvez V; Marcelin AG
Nat Commun; 2021 Feb; 12(1):844. PubMed ID: 33558507
[TBL] [Abstract][Full Text] [Related]
17. Intrathecal expression of IL-5 and humoral response in patients with tick-borne encephalitis.
Grygorczuk S; Czupryna P; Pancewicz S; Świerzbińska R; Kondrusik M; Dunaj J; Zajkowska J; Moniuszko-Malinowska A
Ticks Tick Borne Dis; 2018 May; 9(4):896-911. PubMed ID: 29602685
[TBL] [Abstract][Full Text] [Related]
18. Factors determining immunological response to vaccination against tick-borne encephalitis virus in older individuals.
Lindblom P; Wilhelmsson P; Fryland L; Matussek A; Haglund M; Sjöwall J; Vene S; Nyman D; Forsberg P; Lindgren PE
PLoS One; 2014; 9(6):e100860. PubMed ID: 24967619
[TBL] [Abstract][Full Text] [Related]
19. Delayed humoral immunity in a patient with severe tick-borne encephalitis after complete active vaccination.
Kleiter I; Jilg W; Bogdahn U; Steinbrecher A
Infection; 2007 Feb; 35(1):26-9. PubMed ID: 17297586
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests.
van Dam P; Huizing M; Roelant E; Hotterbeekx A; De Winter FHR; Kumar-Singh S; Moons P; Amajoud Z; Vulsteke C; Croes L; Janssens A; Berneman Z; Prenen H; Meuris L; Vanden Berghe W; Smits E; Peeters M
Eur J Cancer; 2021 May; 148():328-339. PubMed ID: 33773276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
